相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Carolina Schinke et al.
BLOOD (2015)
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60years of age
Sarah A. Buckley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome
Simona Colla et al.
CANCER CELL (2015)
Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome
Kelly Roveran Genga et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I. Ganan-Gomez et al.
LEUKEMIA (2015)
Environmental and chemotherapeutic agents induce breakage at genes involved in leukemia-causing gene rearrangements in human hematopoietic stem/progenitor cells
Ryan G. Thys et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Fanconi anemia and the development of leukemia
Blanche P. Alter et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit
Hind Medyouf et al.
CELL STEM CELL (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
The bone marrow niche for haematopoietic stem cells
Sean J. Morrison et al.
NATURE (2014)
Impact of genomic damage and ageing on stem cell function
Axel Behrens et al.
NATURE CELL BIOLOGY (2014)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
Rami S. Komrokji et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
Maria Teresa Voso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The ageing haematopoietic stem cell compartment
Hartmut Geiger et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Amanda Cashen et al.
ANNALS OF HEMATOLOGY (2012)
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
David R. Steensma
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2012)
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
BLOOD (2012)
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience
Mathilde Lamarque et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors
Stefani Parmentier et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Azra Raza et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes
Hongyan Tong et al.
LEUKEMIA & LYMPHOMA (2012)
Historical perspectives on myelodysplastic syndromes
David P. Steensma
LEUKEMIA RESEARCH (2012)
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Azra Raza et al.
NATURE REVIEWS CANCER (2012)
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
Kiran Naqvi et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Elias Jabbour et al.
CANCER (2011)
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
Matteo G. Della Porta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
Kiran Naqvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Sigurdur Y. Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Telomere length in myelodysplastic syndromes
Dana E. Rollison et al.
LEUKEMIA & LYMPHOMA (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Spatial Clustering of Myelodysplastic Syndromes (MDS) in the Seattle-Puget Sound Region of Washington State
Michelle E. Ross et al.
CANCER CAUSES & CONTROL (2010)
The Epidemiology of Myelodysplastic Syndromes
Mikkael A. Sekeres
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
Stuart L. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Marc H. G. P. Raaijmakers et al.
NATURE (2010)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
Matteo Giovanni Della Porta et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E. J. Feldman et al.
LEUKEMIA (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome
Thomas Fong et al.
HAEMATOLOGICA (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
ChunKang Chang et al.
BLOOD (2007)
A multicenter phase 2 study of the famesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Pierre Fenaux et al.
BLOOD (2007)
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
Hagop Kantarjian et al.
CANCER (2007)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Peter Valent et al.
LEUKEMIA RESEARCH (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes
A Raza et al.
LEUKEMIA & LYMPHOMA (2006)
Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries
B Chen et al.
LEUKEMIA (2005)
The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment
JM Bennett et al.
HEMATOLOGY (2005)
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
MR Weihrauch et al.
LEUKEMIA & LYMPHOMA (2004)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience
I Lobe et al.
LEUKEMIA (2003)
Expression and prognostic significance of Bcl-2 family proteins in Myelodysplastic syndromes
D Boudard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine
M Lübbert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes
K Shimazaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
